gridegalutamide
Term · Oncology and biomedicine · MLC-T-ONC-014039
An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, gridegalutamide causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).
| Identifier | MLC-T-ONC-014039 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | AR degrader CC-94676; Androgen Receptor Degrader CC-94676 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014039",
"term": "gridegalutamide",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, gridegalutamide causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).",
"synonyms": [
"AR degrader CC-94676",
"Androgen Receptor Degrader CC-94676"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/gridegalutamide/"
}
Record 8,201 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.